Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads

Among forty-two tested quinoline-based compounds, twenty-three exhibited significant anti-tubercular activity against Mycobacterium tuberculosis.

• Compounds 3b and 3c showed excellent anti-TB activity with minimum inhibitory concentrations (MIC) of 0.2 and 0.39μg/mL, respectively.
• These two compounds were found to be more potent than the standard anti-TB drugs currently in clinical use.
• All active compounds with MIC values ≤6.25μg/mL demonstrated low toxicity against Human Embryonic Kidney 293T cell lines.
• The findings indicate that these synthesized quinoline derivatives may serve as promising candidates for new TB treatments.

AI simplified